Novonesis (0Q4U) Share Forecast & Price Target

Compare

9 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0Q4U Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Novonesis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0Q4U Stock 12 Month Forecast

Average Price Target

kr506.50

▲(8.53%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Novonesis in the last 3 months. The average price target is kr506.50 with a high forecast of kr577.00 and a low forecast of kr450.00. The average price target represents a 8.53% change from the last price of kr466.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"379":"kr379","578":"kr578","428.75":"kr428.8","478.5":"kr478.5","528.25":"kr528.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":577,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr577.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":506.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr506.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":450,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr450.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[379,428.75,478.5,528.25,578],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,428.86,440.2553846153846,451.65076923076924,463.04615384615386,474.44153846153847,485.8369230769231,497.2323076923077,508.6276923076923,520.0230769230769,531.4184615384615,542.8138461538462,554.2092307692308,565.6046153846154,{"y":577,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,428.86,434.8323076923077,440.8046153846154,446.7769230769231,452.7492307692308,458.72153846153844,464.69384615384615,470.66615384615386,476.63846153846157,482.6107692307692,488.58307692307693,494.5553846153846,500.5276923076923,{"y":506.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,428.86,430.48615384615385,432.1123076923077,433.73846153846154,435.3646153846154,436.9907692307692,438.61692307692306,440.24307692307696,441.8692307692308,443.49538461538464,445.1215384615385,446.7476923076923,448.37384615384616,{"y":450,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":388.63,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":380.22,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.61,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":434.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":464.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":477.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":414.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":429.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":400.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":428.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr577.00

Average Price Targetkr506.50

Lowest Price Targetkr450.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas WrigglesworthMorgan Stanley

Morgan Stanley

kr577

Buy

23.64%

Upside

Initiated

05/29/25

Novonesis initiated with an Overweight at Morgan StanleyNovonesis initiated with an Overweight at Morgan Stanley

Charles EdenUBS

UBS

kr450→kr530

Buy

13.57%

Upside

Upgraded

05/27/25

UBS upgrades Novonesis (0Q4U) to a Buy

Sebastian BrayBerenberg Bank

Berenberg Bank

kr485→kr510

Buy

9.28%

Upside

Reiterated

05/12/25

Novonesis price target raised to DKK 510 from DKK 485 at BerenbergNovonesis price target raised to DKK 510 from DKK 485 at Berenberg

Patrick RoquasKepler Capital

Kepler Capital

kr435→kr450

Hold

-3.57%

Downside

Reiterated

05/08/25

Kepler Capital Sticks to Its Hold Rating for Novonesis (0Q4U)

Alex SloaneBarclays

Barclays

kr500→kr490

Buy

5.00%

Upside

Reiterated

03/28/25

Novonesis A/S (NSISB:DC) PT Lowered to DKK490 at BarclaysBarclays analyst Alex Sloane lowered the price target on Novonesis A/S (NSISB:DC) to DKK490.00 (from DKK500.00) while maintaining a Overweight rating.

Charles Bentley, CFAJefferies

Jefferies

kr500

Buy

7.14%

Upside

Reiterated

03/25/25

Jefferies Reiterates Buy Rating on Novonesis A/S (NSISB:DC)Jefferies analyst Charlie Bentley reiterated a Buy rating and DKK500.00 price target on Novonesis A/S (NSISB:DC).

Adrian NgCFRA

CFRA

kr450

Hold

-3.57%

Downside

Reiterated

03/07/25

CFRA Reiterates Hold Rating on Novonesis A/S (NSISB:DC)CFRA analyst Adrian Ng reiterated a Hold rating and DKK450.00 price target on Novonesis A/S (NSISB:DC).

Chetan UdeshiJ.P. Morgan

J.P. Morgan

kr520→kr545

Buy

16.78%

Upside

Reiterated

03/05/25

Novonesis A/S (NSISB:DC) PT Raised to DKK545 at JPMorganJPMorgan analyst Chetan Udeshi raised the price target on Novonesis A/S (NSISB:DC) to DKK545.00 (from DKK520.00) while maintaining a Overweight rating.

Ranulf OrrCiti

Citi

kr390→kr400

Sell

-14.29%

Downside

Downgraded

10/17/24

Novonesis downgraded to Sell from Neutral at CitiNovonesis downgraded to Sell from Neutral at Citi

Virginie Boucher-FerteDeutsche Bank

Deutsche Bank

kr470→kr500

Buy

7.14%

Upside

Reiterated

09/20/24

Novonesis price target raised to DKK 500 from DKK 470 at Deutsche BankNovonesis price target raised to DKK 500 from DKK 470 at Deutsche Bank

Georgina Fraser CFAGoldman Sachs

Goldman Sachs

kr500→kr560

Buy

20.00%

Upside

Reiterated

09/02/24

Novonesis A/S (NSISB:DC) PT Raised to DKK560 at Goldman SachsGoldman Sachs analyst Georgina Fraser raised the price target on Novonesis A/S (NSISB:DC) to DKK560.00 (from DKK500.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas WrigglesworthMorgan Stanley

Morgan Stanley

kr577

Buy

23.64%

Upside

Initiated

05/29/25

Novonesis initiated with an Overweight at Morgan StanleyNovonesis initiated with an Overweight at Morgan Stanley

Charles EdenUBS

UBS

kr450→kr530

Buy

13.57%

Upside

Upgraded

05/27/25

UBS upgrades Novonesis (0Q4U) to a Buy

Sebastian BrayBerenberg Bank

Berenberg Bank

kr485→kr510

Buy

9.28%

Upside

Reiterated

05/12/25

Novonesis price target raised to DKK 510 from DKK 485 at BerenbergNovonesis price target raised to DKK 510 from DKK 485 at Berenberg

Patrick RoquasKepler Capital

Kepler Capital

kr435→kr450

Hold

-3.57%

Downside

Reiterated

05/08/25

Kepler Capital Sticks to Its Hold Rating for Novonesis (0Q4U)

Alex SloaneBarclays

Barclays

kr500→kr490

Buy

5.00%

Upside

Reiterated

03/28/25

Charles Bentley, CFAJefferies

Jefferies

kr500

Buy

7.14%

Upside

Reiterated

03/25/25

Jefferies Reiterates Buy Rating on Novonesis A/S (NSISB:DC)Jefferies analyst Charlie Bentley reiterated a Buy rating and DKK500.00 price target on Novonesis A/S (NSISB:DC).

Adrian NgCFRA

CFRA

kr450

Hold

-3.57%

Downside

Reiterated

03/07/25

CFRA Reiterates Hold Rating on Novonesis A/S (NSISB:DC)CFRA analyst Adrian Ng reiterated a Hold rating and DKK450.00 price target on Novonesis A/S (NSISB:DC).

Chetan UdeshiJ.P. Morgan

J.P. Morgan

kr520→kr545

Buy

16.78%

Upside

Reiterated

03/05/25

Ranulf OrrCiti

Citi

kr390→kr400

Sell

-14.29%

Downside

Downgraded

10/17/24

Novonesis downgraded to Sell from Neutral at CitiNovonesis downgraded to Sell from Neutral at Citi

Virginie Boucher-FerteDeutsche Bank

Deutsche Bank

kr470→kr500

Buy

7.14%

Upside

Reiterated

09/20/24

Novonesis price target raised to DKK 500 from DKK 470 at Deutsche BankNovonesis price target raised to DKK 500 from DKK 470 at Deutsche Bank

Georgina Fraser CFAGoldman Sachs

Goldman Sachs

kr500→kr560

Buy

20.00%

Upside

Reiterated

09/02/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novonesis

1 Month

xxx

Success Rate

13/16 ratings generated profit

Average Return

+1.36%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 81.25% of your transactions generating a profit, with an average return of +1.36% per trade.

3 Months

xxx

Success Rate

12/18 ratings generated profit

Average Return

+1.67%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.67% per trade.

1 Year

Charles EdenUBS

Success Rate

10/14 ratings generated profit

Average Return

+11.28%

upgraded a buy rating 8 days ago

Copying Charles Eden's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +11.28% per trade.

2 Years

xxx

Success Rate

11/14 ratings generated profit

Average Return

+13.13%

upgraded a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +13.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q4U Analyst Recommendation Trends

Rating

Dec 24

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0Q4U has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0Q4U average Analyst price target in the past 3 months is 506.50.

Each month's total comprises the sum of three months' worth of ratings.

0Q4U Financial Forecast

0Q4U Earnings Forecast

Next quarter’s earnings estimate for 0Q4U is kr4.92 with a range of kr3.11 to kr6.71. The previous quarter’s EPS was kr3.13. 0Q4U beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.04% of the time in the same period. In the last calendar year 0Q4U has Preformed in-line its overall industry.

0Q4U Sales Forecast

Next quarter’s sales forecast for 0Q4U is kr7.73B with a range of kr7.62B to kr7.86B. The previous quarter’s sales results were kr8.04B. 0Q4U beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 40.77% of the time in the same period. In the last calendar year 0Q4U has Preformed in-line its overall industry.

0Q4U Stock Forecast FAQ

What is GB:0Q4U’s average 12-month price target, according to analysts?

Based on analyst ratings, Novonesis’s 12-month average price target is 506.50.

What is GB:0Q4U’s upside potential, based on the analysts’ average price target?

Novonesis has 8.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novonesis a Buy, Sell or Hold?

Novonesis has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Novonesis’s share price target?

The average share price target for Novonesis is 506.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr577.00 ,and the lowest forecast is kr450.00. The average share price target represents 8.53% Increase from the current price of kr466.67.

What do analysts say about Novonesis?

Novonesis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Novonesis?

To buy shares of GB:0Q4U, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novonesis (0Q4U) Share Forecast & Price Target

0Q4U Analyst Ratings

0Q4U Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novonesis

0Q4U Analyst Recommendation Trends

0Q4U Financial Forecast

0Q4U Earnings Forecast

0Q4U Sales Forecast

0Q4U Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts